ADHD Meds May Improve Menopausal Brain Fog, Review Finds
Commonly prescribed attention-deficit/hyperactivity disorder medications like lisdexamfetamine and atomoxetine may improve self-reported executive function during perimenopause and menopause, according to a scoping review presented at the 2026 Annual Meeting of the Menopause Society in San Diego.
-
Key Clinical Takeaways:
- ADHD medications such as Vyvanse and Strattera showed positive effects on self-reported executive function scores in women experiencing menopausal brain fog.
- The review found little to no significant improvement on objective cognitive tests measuring memory and processing speed.
- Experts caution that these drugs lack FDA approval for menopausal brain fog and carry risks including cardiovascular effects and potential dependence.
Scoping Review Evaluates Five Studies on Executive Dysfunction
The review analyzed five studies focusing on females aged 45 to 60 whose last menstrual period occurred within the past 10 years. Researchers examined how ADHD medications impact outcome measures of cognition and ADHD severity in this demographic. With lisdexamfetamine, scores on the Brown Attention Deficit Disorder Scale dropped from 35.7 to 21.2, compared with 29.8 for a placebo. Atomoxetine decreased scores from 38.6 to 25.5, compared with 30.1 for a placebo. However, the review identified no significant benefit on objective cognitive tests measuring memory and processing speed.
Symptom Severity Predicts Menopausal Burden More than Formal Diagnosis
Jennifer Tat, lead author of the study, noted that symptom severity rather than a formal ADHD diagnosis predicted menopausal burden. Many women go undiagnosed, meaning standard chart diagnoses miss those most at risk. Sara Vaughn, Chief Medical Officer at Clair Health, who was not involved in the study, described the findings as interesting and hypothesis-generating. Vaughn cautioned that the research does not yet establish ADHD medications as a standard treatment for menopausal brain fog, pointing to small sample sizes, reliance on self-reported measures, and potential cardiovascular risks and misuse potential associated with stimulants.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.